Hao Zhang

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Epithelial Mesenchymal Transition

Top Venues

Journal of medicinal chemistry

Future medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry 66 (2) (2023)
Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry 66 (2) (2023)
Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry (2023)
Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry 66 (2) (2023)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry 66 (1) (2022)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry (2022)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry 66 (1) (2022)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry 66 (1) (2022)
Hao Zhang, Ya Bao, Chenglong Liu, Jianqi Li, Di Zhu, Qingwei Zhang
Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors. Future medicinal chemistry 13 (10) (2021)